title: Recurrent pleomorphic adenoma: results of surgical treatment.
abstract: BACKGROUND
  Recurrent parotid pleomorphic adenoma surgery increases the risk of facial nerve injury, and there is also a risk of ulterior recurrence.
  
  
  METHODS
  Postoperative results from 62 consecutive patients operated for recurrent pleomorphic adenoma were analyzed. It was the first recurrence for 49 patients (79%), the second or more for 13 patients (21%).
  
  
  RESULTS
  Total parotidectomy was performed in 69.4% of cases. Skin resection was performed in 47 patients (75.8%). Resection of a facial nerve branch was performed in seven patients (11.3%). Pathologic examination findings revealed carcinoma ex pleomorphic adenoma in 10/62 cases (16.1%) and microscopic multinodular disease in 39 patients (62.9%). Nine patients had preoperative facial palsy, 95% had postoperative facial paralysis ≥ grade II (House-Brackmann scale), and 11.3% still had ≥ grade III facial palsy after 1 year. Six patients developed another recurrence after our intervention (9.68%). Moreover, carcinoma was discovered after a new intervention in 40% of these patients. Initial partial parotid surgery [hazard ratio (HR) = 8.477, P = 0.008], microscopic multinodular recurrent disease (HR = 11.717, P = 0.005), and ≥ 1 recurrence number (HR = 10.608, P = 0.01) were associated with increased risk of ulterior recurrence.
  
  
  CONCLUSIONS
  Surgery is recommended in pleomorphic adenoma recurrence because of the high rate of carcinoma ex pleomorphic adenoma (16.1%). Nevertheless, a definitive facial paralysis ≥ grade III rate of 11.3% is reported after multiple nerve dissection. New recurrence after surgery is less frequent if the initial treatment for pleomorphic adenoma is total parotidectomy.
authors.affiliation: Department of Head and Neck Surgery, CHU, Montpellier, France. m-makeieff@chu-montpellier.fr
authors.forename: Marc
authors.initials: M
authors.lastname: Makeieff
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Pelliccia
authors.forename: Flavie
authors.initials: F
authors.lastname: Letois
authors.forename: Grégoire
authors.initials: G
authors.lastname: Mercier
authors.forename: Sebastien
authors.initials: S
authors.lastname: Arnaud
authors.forename: Cartier
authors.initials: C
authors.lastname: César
authors.forename: Renaud
authors.initials: R
authors.lastname: Garrel
authors.forename: Louis
authors.initials: L
authors.lastname: Crampette
authors.forename: Bernard
authors.initials: B
authors.lastname: Guerrier
mesh_terms: D008949:Adenoma, Pleomorphic / Q000150:complications* / Q000473:pathology / Q000601:surgery; D000293:Adolescent; D000328:Adult; D000368:Aged; D020220:Facial Nerve Injuries / Q000209:etiology* / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000209:etiology* / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D010307:Parotid Neoplasms / Q000150:complications* / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult